<SEC-DOCUMENT>0001193125-22-299586.txt : 20221207
<SEC-HEADER>0001193125-22-299586.hdr.sgml : 20221207
<ACCEPTANCE-DATETIME>20221206204831
ACCESSION NUMBER:		0001193125-22-299586
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221206
FILED AS OF DATE:		20221207
DATE AS OF CHANGE:		20221206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		221448969

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d356697d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated December 6, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d356697dex991.htm">Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December 6, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d356697dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g35669703.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces GMP Manufacturing Process Developed for IMP761, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT>
<FONT STYLE="white-space:nowrap">LAG-3</FONT> Agonist for Autoimmune Disease </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Achievement Allows
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> Studies in 1H&#146;2023 and </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Subsequent Clinical Testing of IMP761 to Address
Root Cause of Autoimmune Diseases </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 06 December </B><B>2022 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP)
(&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant
manufacturing process has been established for IMP761, its proprietary preclinical candidate for autoimmune diseases. The 200L scale attained by Northway Biotech, an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> biopharmaceutical contract development and manufacturing organisation (CDMO), will ensure supply of IMP761 for
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and ensuing clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the first immunosuppressive agonist antibody to <FONT
STYLE="white-space:nowrap">LAG-3</FONT> acting upstream on activated T cells to target the root cause of self-antigen-specific T cell induced disease, IMP761 is a potential game-changer in how autoimmune diseases are treated. <FONT
STYLE="white-space:nowrap">Pre-clinical</FONT> testing of IMP761 in oligoarticular juvenile idiopathic arthritis, published in <U>Pediatric Research</U> in May 2021, showed that agonistic activation of <FONT STYLE="white-space:nowrap">LAG-3</FONT>
in this <FONT STYLE="white-space:nowrap">Th1-driven</FONT> autoimmune disease setting resulted in a decreased secretion of nearly all measured cytokines, and that of <FONT STYLE="white-space:nowrap">IL-10,</FONT>
<FONT STYLE="white-space:nowrap">IL-12,</FONT> <FONT STYLE="white-space:nowrap">IL-1&szlig;,</FONT> <FONT STYLE="white-space:nowrap">IL-4,</FONT> and <FONT STYLE="white-space:nowrap">IL-6</FONT> reached the level of significance (p &lt; 0.01). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CEO Marc Voigt said:</B> &#147;We are pleased to have a GMP manufacturing process for IMP761 in hand with our manufacturing partner Northway
Biotech as we move towards initiating <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in the first half of 2023 and subsequent clinical development. As a <FONT STYLE="white-space:nowrap">first-in-class</FONT> <FONT
STYLE="white-space:nowrap">LAG-3</FONT> immunosuppressive antibody, IMP761 has been designed to address the root cause of autoimmune diseases by specifically silencing self-reactive exhausted effector T cells that express <FONT
STYLE="white-space:nowrap">LAG-3</FONT> and accumulate at disease sites.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vladas Algirdas Bumelis, CEO</B> <B>of Northway Biotech stated:</B>
&#147;Our world-class team in Vilnius worked diligently and expeditiously to develop the capability to produce this unique <FONT STYLE="white-space:nowrap">LAG-3</FONT> antibody at 200L scale. We continue to work closely with Immutep to accelerate
the development of its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">LAG-3</FONT> therapy and help advance this novel approach against autoimmune diseases that impair
so many patients on a global basis.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing process was developed on a platform technology of <U>Northway Biotech</U> resulting in a
final product of high quality. An engineering and a GMP manufacturing run at 200L have been successfully performed for bulk drug substance and final filled drug product, proving the robustness and reproducibility of the developed manufacturing
process. A stability program according to ICH guidelines has been initiated and will support the definition of a shelf life of the drug in its current formulation. After final release and batch certification, the produced material will be used for
further preclinical development, including <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, and Immutep&#146;s planned clinical trials of IMP761. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP761 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761 is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive agonist antibody to <FONT STYLE="white-space:nowrap">LAG-3.</FONT> As a targeted immunosuppressive </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 33, Australia Square, 264 George Street,
Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g35669703.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">antibody, IMP761 has the potential to address the
root cause of autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at the disease site and which express <FONT STYLE="white-space:nowrap">LAG-3</FONT> as an &#147;exhaustion marker&#148; after being repeatedly
stimulated with dominant self-peptides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In early 2019, Immutep reported encouraging <FONT STYLE="white-space:nowrap">pre-clinical</FONT> results from its
studies with IMP761. The in vivo studies showed that IMP761 decreases inflammatory T cell infiltration induced by intra-dermal injection of an antigen. These findings were published in the <U>Journal of Immunology</U> in January 2020. Additional <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> research findings from a juvenile arthritis ex vivo model were published in <U>Pediatric Research</U> in May 2021. In these studies, IMP761 was shown to decrease effector T cell cytokine secretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology
company leading the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring
innovative treatment options to market for patients and to maximise value to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s lead product candidate is eftilagimod alpha
(&#147;efti&#148; or &#147;IMP321&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of <FONT
STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> product candidates, including antibodies for immune response modulation, are licensed to and being developed by
Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim McCarthy, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement has been approved for release by the Board of Immutep Limited. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g35669703.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g35669703.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M4W]J*>DE\47HUU/3*ZCUPH * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M3B*SG5C5A22LH)4ZDN64>6*22:D[Z7;2OL?I<./P_I7U9^N;>5@H * "@ H
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M8J45&51Q7+"3BDO=@M4WK*5GJE=_:H&./3^E>]M\C] V\K!0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MIGC&QMTN(Y(Y$M5U![F-0DB@A ]U(!QC XH P_V$O^0A\2O^O/PM_P"C]=H
M^DOVHO#NFZ[\%_%T][!&UUX?MH==TJX909;2\LKF!7,3GE!-:27$# '#+-ST
M%'Z!^A\^?L)ZK=&+XBZ&SLUE!+X?U:!"24AN;E-1L[EE&< R16EKGU\@>E '
MZ#T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 '_#^= 'YR^!N/V@[?V\<>)/_ $/6*^7P^F9KRJU/_;C\IRW3BF/EB\1_
M[E/2_P!K+_CY\#_]<->_]&:375G.^'])_P#MIZW&_P 66^E;_P!QGT+\'?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MK0O$>JW<'PK:YO?,/B'1;Y]8<PP1?;]1M-$M[G>%5,02&X2[F\N'8,!QC:F
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M]A+_ )"'Q*_Z\_"W_H_7: /T6H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#G;7PEX:LIKN>TT73[:6^2[CO&A
M@5!<)?R-+>I*BX5EGD9F<8^8L2>2: -1M-L&2PC-I;%-+DBETU/)0+82PV\M
MI%):*!B!EM9IH1LQ^[E9/NL00#.;PKX<?4AJ[:+IQU-;A+S[9]FC$IO(D\N.
M\; VO>*GRB9@9   &X% &C?Z;8ZI;&SU"VCNK9GCD,4H.W?$P>-P5((96 ((
M(Q0 ZPT^QTNTBL=.M(+&S@#"&VMHDAACWNTDA"( -SR.[LQR69V9B222 1G2
MM-*RJ;&UQ/?PZI-F"/\ >ZE;-;O;WT@V_-=QO:6I60_,#;QD'Y!@ FELK2=[
M>2:VAD>TN#=VK/&I:WNS!-;-<Q$CY)S;W$\>\<[9G7.&- "V]G:V:E+:WA@5
MKBYNF6*-4!N;N62>ZG.T?ZZ::65W;JS2,3UH SKGPYH5WI]MI5QI-A+IUG(D
MMG9M;QB&SECWB.6T50/LTBB20!HRI D89PQ! )H=$TBVLK/3;?3;*"PTZ:&X
ML;..VB2WM+BWE-Q#/!$J[8YDG)D#@;MY+9W$F@"S'864-U=WL5I;QW=]';Q7
MMRD,:SW<=HLJVJ7,H7=,L*33*@<G:)6 X- &7IOA;PYH]R;O2]$TVPN?+>%9
MK:UBB>&&1Q))! 57_1H&=59HX@BDJI(.T8 -=+2VBN9[Q((DNKB&W@N+A459
MIH;1IVMHI) -SQQ-=7)12<*9Y,?>- %<:5IJV\=J+&U%M%>_VC' (4$27XO3
MJ7VQ4Q@7/]H,USYG7S27SNYH H3>%O#MSJ9UF;1[%]4:6WF:_,(6Y>:T2..V
MEDD4@N\4<,2J6R0L:CH * +TND:7/'>PS:?:2PZE<175_$\$;)>74"6T4-Q<
M*5_>SI'96BJYRRBUBP1L& "9+"SB-Z4M8%;49/-OR(D!O)!;168>YX_?,+2"
M&'YL_)$J] !0!':Z7IUDT+VEE;6[VUC#IENT4*(T&G6YS!8QLHREK&0"L8^4
M=A0!-<6=K=&W^TP13FTN([NV\V-7\BZB#K'/%N!V2JKN PP1O/K0!#JFEZ=K
M6GW6E:M96VHZ9?0M;WMA>0I<6EU ^-\-Q!("LL9P,JP(- &)X;\#>#O![7;^
M%?#&A^'GOUA6];1]-M;!KI;8R&!9S;QKYHC,TI4-G'F-CK1MY!MY'54 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M,4?6L=_S]J_C_D']J9]_T%XO[I__ "(?\+$^+_\ T,OC3_R=_P#C%'UK'?\
M/VK^/^0?VIGW_07B_NG_ /(A_P +$^+_ /T,OC3_ ,G?_C%'UK'?\_:OX_Y!
M_:F??]!>+^Z?_P B'_"Q/B__ -#+XT_\G?\ XQ1]:QW_ #]J_C_D']J9]_T%
MXO[I_P#R(?\ "Q/B_P#]#+XT_P#)W_XQ1]:QW_/VK^/^0?VIGW_07B_NG_\
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M_P B'_"Q/B__ -#+XT_\G?\ XQ1]:QW_ #]J_C_D']J9]_T%XO[I_P#R(?\
M"Q/B_P#]#+XT_P#)W_XQ1]:QW_/VK^/^0?VIGW_07B_NG_\ (A_PL3XO_P#0
MR^-/_)W_ .,4?6L=_P _:OX_Y!_:F??]!>+^Z?\ \B'_  L3XO\ _0R^-/\
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M  L3XO\ _0R^-/\ R=_^,4?6L=_S]J_C_D']J9]_T%XO[I__ "(?\+$^+_\
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M7B_NG_\ (A_PL3XO_P#0R^-/_)W_ .,4?6L=_P _:OX_Y!_:F??]!>+^Z?\
M\B'_  L3XO\ _0R^-/\ R=_^,4?6L=_S]J_C_D']J9]_T%XO[I__ "(?\+$^
M+_\ T,OC3_R=_P#C%'UK'?\ /VK^/^0?VIGW_07B_NG_ /(A_P +$^+_ /T,
MOC3_ ,G?_C%'UK'?\_:OX_Y!_:F??]!>+^Z?_P B'_"Q/B__ -#+XT_\G?\
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ML3XO_P#0R^-/_)W_ .,4?6L=_P _:OX_Y!_:F??]!>+^Z?\ \B'_  L3XO\
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M,4?6L=_S]J_C_D']J9]_T%XO[I__ "(?\+$^+_\ T,OC3_R=_P#C%'UK'?\
M/VK^/^0?VIGW_07B_NG_ /(A_P +$^+_ /T,OC3_ ,G?_C%'UK'?\_:OX_Y!
M_:F??]!>+^Z?_P B'_"Q/B__ -#+XT_\G?\ XQ1]:QW_ #]J_C_D']J9]_T%
MXO[I_P#R(?\ "Q/B_P#]#+XT_P#)W_XQ1]:QW_/VK^/^0?VIGW_07B_NG_\
M(A_PL3XO_P#0R^-/_)W_ .,4?6L=_P _:OX_Y!_:F??]!>+^Z?\ \B'_  L3
MXO\ _0R^-/\ R=_^,4?6L=_S]J_C_D']J9]_T%XO[I__ ")^H&/\Y-?6G[#;
M^KL,?YR: M_5V&/\Y- 6_J[#'^<F@+?U=AC_ #DT!;^KL,?YR: M_5V&/\Y-
M 6_J[#'^<F@+?U=AC_.30%OZNPQ_G)H"W]788_SDT!;^KL,?YR: M_5V&/\
M.30%OZNPQ_G)H"W]788_SDT!;^KL,?YR: M_5V&/\Y- 6_J[#'^<F@+?U=AC
M_.30%OZNPQ_G)H"W]788_P Y- 6_J[#'^<F@+?U=AC_.30%OZNPQ_G)H"W]7
M88_SDT!;^KL,?YR: M_5V&/\Y- 6_J[#'^<F@+?U=AC_ #DT!;^KL,?YR: M
M_5V&/\Y- 6_J[#'^<F@+?U=AC_.30%OZNPQ_G)H"W]788_SDT!;^KL,?YR:
MM_5V&/\ .30%OZNPQ_G)H"W]788_SDT!;^KL,?YR: M_5V&/\Y- 6_J[#'^<
MF@+?U=AC_.30%OZNPQ_G)H"W]788_P Y- 6_J[#'^<F@+?U=AC_.30%OZNPQ
M_G)H"W]788_SDT!;^KL,?YR: M_5V&/\Y- 6_J[#'^<F@+?U=AC_ #DT!;^K
ML,?YR: M_5V&/\Y- 6_J[#'^<F@+?U=AC_.30%OZNPQ_G)H"W]788_SDT!;^
MKL,?YR: M_5V&/\ .30%OZNPQ_G)H"W]788_SDT!;^KL,?YR: M_5V&/\Y-
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7@+?U=AC_ #DT!;^KL,?YR: M_5V?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
